Surufatinib and Toripalimab Combined With Chemotherapy for Second-line Treatment of Advanced RAS/BRAF Mutant and Microsatellite Stable Colorectal Cancer

NCT04653480 Phase 2 UNKNOWN

To determine the efficacy and safety of surufatinib, toripalimab and chemotherapy in second-line RAS/BRAF mutant and MSS colorectal cancer

Details

Lead sponsor	Zhejiang University
Phase	Phase 2
Status	UNKNOWN
Enrolment	61
Start date	2021-02-01
Completion	2025-06

Conditions

• Colorectal Cancer

Interventions

• Surufatinib
• Toripalimab
• chemotherapy

Primary outcomes

• Overall Response Rate — 2 months
  the proportion of patients in a trial whose tumor is destroyed or significantly reduced by a drug. ORR is generally defined as the sum of complete responses (CRs) - patients with no detectable evidence of a tumor over a specified time period - and partial responses (PRs) - patients with a decrease in tumor size over a specified time period.

Countries

China